Clinical trials: Anthracyclines
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols.
- Conditions
- Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity, Childhood Cancer Survivors
- Trial name
- CARDIO-PED (NCT07253077)
- Testing
- Biomarker detection
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiotoxicity, Childhood Cancer
Prediction of Delayed Toxic Cardiomyopathy in Children
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.
- Trial name
- SpeckleAnthra2 (NCT05781672)
- Testing
- cardiac ultrasound with speckle tracking analysis
- Where
- France
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Myocardial Function, Echographic Parameters Obtaind by Speckle Tracking
Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood
The main goal of this study is to compare the values of echocardiographic parameters obtained by Speckle Traking analysis on myocardial function among patients under 18 years treated with anthracyclines in childhood, with healthy…
- Conditions
- Myocardial Function, Echographic Parameters Obtaind by Speckle Tracking, Chilhood Cancers
- Trial name
- SPECKLEANTHRA (NCT02893787)
- Testing
- Speckle Tracking Echocardiography
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine